{"title": "Clinical Characteristics of Patients with Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China", "doi": "10.1101/2020.03.02.20029306", "citation_id": "2020.03.02.20029306v1", "date": "2020-03-03", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.02.20029306", "abstract": "<p>Abstract\nBackground: A new virus broke out in Wuhan, Hubei, China, and was later named 2019 novel coronavirus (2019-nCoV). The clinical characteristics of severe pneumonia caused by 2019-nCoV are still not clear.\nObjectives: The aim of this study was to explore the clinical characteristics and risk factors of the severe pneumonia caused by the 2019-nCoV in Wuhan, China.\nMethod: The study included patients hospitalized at the central hospital of Wuhan who had been diagnosed with a pneumonia caused by the novel coronavirus. Clinical features, chronic co-morbidities, demographic data, laboratory examinations, and chest computed tomography (CT) scans were reviewed through electronic medical records. SPSS was used for data analysis to explore the clinical characteristics and risk factors of the patients with the severe pneumonia.\nResults: A total of 110 patients diagnosed with 2019 novel coronavirus pneumonia were included in the study, including 38 with severe pneumonia and 72 with non-severe pneumonia. Statistical analysis showed that advanced age, an increase of D-dimer, and a decrease of lymphocytes were characteristics of the patients with severe pneumonia. Moreover, in the early stage of the disease, chest CT scans of patients with the severe pneumonia showed the illness can progress rapidly.\nConclusions: Advanced age, lymphocyte decline, and D-dimer elevation are important characteristics of patients with severe pneumonia. Clinicians should focus on these characteristics to identify high-risk patients at an early stage.</p>", "twitter_description": "Abstract Background: A new virus broke out in Wuhan, Hubei, China, and was later named 2019 novel coronavirus (2019-nCoV). The clinical characteristics of severe pneumonia caused by 2019-nCoV are still not clear. Objectives: The aim of this study was to explore the clinical characteristics and risk factors of the severe pneumonia caused by the 2019-nCoV in Wuhan, China. Method: The study included patients hospitalized at the central hospital of Wuhan who had been diagnosed with a pneumonia caused by the novel coronavirus. Clinical features, chronic co-morbidities, demographic data, laboratory examinations, and chest computed tomography (CT) scans were reviewed through electronic medical records. SPSS was used for data analysis to explore the clinical characteristics and risk factors of the patients with the severe pneumonia. Results: A total of 110 patients diagnosed with 2019 novel coronavirus pneumonia were included in the study, including 38 with severe pneumonia and 72 with non-severe pneumonia. Statistical analysis showed that advanced age, an increase of D-dimer, and a decrease of lymphocytes were characteristics of the patients with severe pneumonia. Moreover, in the early stage of the disease, chest CT scans of patients with the severe pneumonia showed the illness can progress rapidly. Conclusions: Advanced age, lymphocyte decline, and D-dimer elevation are important characteristics of patients with severe pneumonia. Clinicians should focus on these characteristics to identify high-risk patients at an early stage.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nThe research received no funding.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe clinical data of the patients used in the study came from the central hospital of Wuhan and were approved by relevant departments of the hospital.Although the data included in the study included basic information about the patients, laboratory tests and imaging results, and had no privacy implications, the data could not be released at this time, as required by the hospital.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.02.20029306v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.02.20029306v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.02.20029306v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/03/2020.03.02.20029306.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.02.20029306v1", "access_rights": "restricted", "authors": ["Yafei Wang", "Ying Zhou", "Zhen Yang", "Dongping Xia", "Shuang Geng"]}